WO2000066130A1 - Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel - Google Patents
Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel Download PDFInfo
- Publication number
- WO2000066130A1 WO2000066130A1 PCT/FR2000/001086 FR0001086W WO0066130A1 WO 2000066130 A1 WO2000066130 A1 WO 2000066130A1 FR 0001086 W FR0001086 W FR 0001086W WO 0066130 A1 WO0066130 A1 WO 0066130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- acetylsalicylic acid
- clopidogrel
- hydrogen sulfate
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- composition in unit form containing acetylsalicylic acid and clopidogrel hydrogen sulfate
- the present invention relates to a pharmaceutical composition in a unit dosage form containing an association of active principles with antiplatelet activity consisting of acetylsalicylic acid, also known under the brand name Aspirin, and clopidogrel hydrogen sulfate.
- the unit dosage form can be administered orally and preferably consists of a tablet, a capsule or a dose sachet.
- acetylsalicylic acid is used in its acid form and clopidogrel hydrogen sulphate can be used in the form of one or other of its polymorphs known to date and called Form 1 (F1) or Form 2 (F2).
- Form 1 is the salt described in patent EP 281459 and clopidogrel hydrogen sulfate Form 2 is that described in patent application FR 98 07464.
- the therapeutic advantage of the combination of acetylsalicylic acid and of clopidogrel is among others described in patent application WO 97/29753.
- compositions are mentioned there without ever specifying that the pharmaceutically acceptable salt used is clopidogrel hydrogen sulfate. This document always indicates that the composition can be used parenterally or orally and that it is possible to administer the active ingredients according to four modes of administration, namely, both orally, both parenterally or one orally and the other parenterally or vice versa.
- the tablets according to the invention can be obtained by various manufacturing processes such as for example:
- the direct compression process in which the active ingredients and the selected excipients are mixed.
- the mixture obtained is sieved (calibrated) on a previously defined mesh opening grid, in order to homogenize the particle sizes of the constituents.
- a new mixing is carried out to ensure good homogeneity of the active ingredients.
- Specific excipients (example: a flow agent) as well as a lubricant are added and mixed.
- the final mixture obtained is then compressed.
- Dry granulation consists in ensuring that the active ingredients and the selected excipients are mixed, calibrated and then mixed again.
- the mixture is forced between two mobile cylinders, in opposite directions of rotation, in order to obtain, according to the forces exerted, plates of determined mechanical strengths. These plates are calibrated.
- the specific excipients are added and the final mixture compressed.
- Hot melt granulation is a granulation process that can be used when an active ingredient degrades in the presence of water.
- the active ingredients and the selected excipients are calibrated and then mixed.
- the mixture is brought under slow stirring to a temperature slightly higher than that of the melting point of the excipient, mixed under rapid stirring, then cooled to room temperature.
- the grain obtained is calibrated.
- the specific excipients are added and the final mixture compressed.
- An example of a "hot melt” process in a granulator with a fluidized air bed is described below.
- the active ingredients and the selected excipients, except the fusible excipient are calibrated and then transferred to a granulator with a fluidized air bed.
- the whole is mixed by fluidization with supply of hot air, up to a temperature of the mixture slightly lower than that of the melting point of the granulation excipient.
- the molten excipient is then sprayed onto the fluidized mixture.
- the temperature of the fluidizing air is lowered.
- the grain obtained is calibrated.
- the specific excipients are added and the final mixture compressed.
- the capsules and dose sachets are prepared according to techniques well known to those skilled in the art.
- the pharmaceutical compositions according to the invention are used for the treatment of a pathology induced by platelet aggregation including stable or unstable angina, disorders of the cardiovascular and cerebrovascular system such as thromboembolic disorders associated with atherosclerosis and diabetes such as unstable angina, cerebral attack, restenosis after angioplasty, endarterectomy or fitting of metal endovascular prostheses or thromboembolic disorders associated with rethrombosis after thrombolysis, infarction, dementia of ischemic origin, peripheral arterial diseases, hemodialysis, atrial fibrillation or even when using vascular prostheses, bypass surgery, or during radiotherapy to reduce side effects.
- compositions according to the invention are used for the preparation of a medicament intended for the treatment of the pathologies mentioned above and allow the treatment of these pathologies.
- clopidogrel hydrogen sulfate and acetylsalicylic acid are present in a molar ratio of clopidogrel hydrogenosulfate / acetylsalicylic acid comprised between 2.5 and 11, preferably between 5 and 9.
- clopidogrel hydrogen sulfate 1 to 500 mg per day of clopidogrel hydrogen sulfate and 1 to 500 mg per day of acetylsalicylic acid are administered to humans, the doses being expressed in equivalent amounts of clopidogrel in free form.
- clopidogrel hydrogen sulfate is administered and 75 to
- compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 75 mg of acetylsalicylic acid are particularly preferred.
- compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid Preference is also given to compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid.
- Example granulation process by compacting
- Anhydrous lactose ⁇ can be replaced in an equivalent amount with mannitol.
- Example granulation process by compacting
- Mannitol can be replaced in an equivalent amount by anhydrous lactose ⁇ .
- a) 97.875 g of clopidogrel hydrogenosulfate are mixed with 2 g of anhydrous colloidal silica b) 325 g of acetylsalicylic acid, 30 g of corn starch, 124.6 g of mannitol and 60 g of microcrystalline cellulose are added to a) and mixed c)
- the mixture b) is calibrated and then mixed again d) 10.5 g of hydrogenated castor oil are added to c) before the final mixture e)
- the final mixture is compressed to a theoretical unit mass of 650 mg
- the mixture is made in mini-rhôn for 10 minutes between the active ingredients and the diluents.
- the active ingredients are mixed with the mini-rhôn for 10 minutes with the diluents.
- Anhydrous colloidal silica is added to the above mixture and then sieved through a grid of 0.315 mm mesh opening.
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14564800A IL145648A0 (en) | 1999-04-30 | 2000-04-25 | Pharmaceutical composition in unit form containing acetylsalicylic acid and clopidogrel hydrogenosulphate |
CA002371231A CA2371231A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
MXPA01011071A MXPA01011071A (es) | 1999-04-30 | 2000-04-25 | Composicion farmaceutica en forma unitaria que contiene acido acetilsalicilico e hidrogenosulfato de clopidogrel. |
JP2000615014A JP2002543137A (ja) | 1999-04-30 | 2000-04-25 | アセチルサリチル酸およびクロピドグレル硫酸水素塩を含む単位形態における医薬組成物 |
EA200100959A EA200100959A1 (ru) | 1999-04-30 | 2000-04-25 | Фармацевтическая композиция в стандартной форме , содержащая ацетилсалициловую кислоту и гидросульфат клопидогрела |
AU43036/00A AU4303600A (en) | 1999-04-30 | 2000-04-25 | Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate |
PL00351923A PL351923A1 (en) | 1999-04-30 | 2000-04-25 | Pharmaceutical compound in a unitary form containing acetylsalicyclic acid and clopidogrel bisulfate |
NZ514248A NZ514248A (en) | 1999-04-30 | 2000-04-25 | Pharmaceutical composition in a unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate |
EP00922737A EP1178809A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
SK1554-2001A SK15542001A3 (sk) | 1999-04-30 | 2000-04-25 | Farmaceutická kompozícia v jednotkovej forme obsahujúca kombináciu acetylsalicylovej kyseliny a clopidogrel-hydrogensulfátu a jej použitie |
BR0010194-0A BR0010194A (pt) | 1999-04-30 | 2000-04-25 | Composição farmacêutica sob a forma unitária, contendo o ácido acetilsalicìlico e hidrogenossulfato de clopidogrel |
EEP200100559A EE200100559A (et) | 1999-04-30 | 2000-04-25 | Atsetüülsalitsüülhapet ja klopidogreelvesiniksulfaati sisaldav farmatseutiline kompositsioon üksikannusvormis |
KR1020017013830A KR20020005735A (ko) | 1999-04-30 | 2000-04-25 | 아세틸살리실산 및 클로피도그렐 황산수소염을 포함하는단위 형태의 제약 조성물 |
IS6084A IS6084A (is) | 1999-04-30 | 2001-09-25 | Lyfjasamsetning á einingaformi sem inniheldur asetýlsalisílsýru og klópidógrel vetnissúlfat |
NO20015295A NO20015295L (no) | 1999-04-30 | 2001-10-29 | Farmasöytisk preparat i enhetsform inneholdende acetylsalicylsyre og klopidogrelhydrogensulfat |
HK02103639.9A HK1041823A1 (zh) | 1999-04-30 | 2002-05-14 | 含有乙酰水楊酸和氯吡格雷硫酸氫鹽的單位劑型形藥物組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905497A FR2792836B3 (fr) | 1999-04-30 | 1999-04-30 | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
FR99/05497 | 1999-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000066130A1 true WO2000066130A1 (fr) | 2000-11-09 |
Family
ID=9545071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001086 WO2000066130A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1178809A1 (fr) |
JP (1) | JP2002543137A (fr) |
KR (1) | KR20020005735A (fr) |
CN (1) | CN1359294A (fr) |
AR (1) | AR023789A1 (fr) |
AU (1) | AU4303600A (fr) |
BR (1) | BR0010194A (fr) |
CA (1) | CA2371231A1 (fr) |
CZ (1) | CZ20013887A3 (fr) |
EA (1) | EA200100959A1 (fr) |
EE (1) | EE200100559A (fr) |
FR (1) | FR2792836B3 (fr) |
HK (1) | HK1041823A1 (fr) |
HU (1) | HUP0202329A2 (fr) |
IL (1) | IL145648A0 (fr) |
IS (1) | IS6084A (fr) |
MX (1) | MXPA01011071A (fr) |
NO (1) | NO20015295L (fr) |
NZ (1) | NZ514248A (fr) |
PL (1) | PL351923A1 (fr) |
SK (1) | SK15542001A3 (fr) |
TR (1) | TR200103039T2 (fr) |
UY (1) | UY26131A1 (fr) |
WO (1) | WO2000066130A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737411B2 (en) | 2002-08-02 | 2004-05-18 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
US6767913B2 (en) | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
WO2005070464A2 (fr) * | 2004-01-21 | 2005-08-04 | Biofarma Ilac Sanayi Ve Ticaret A.S. | Formulation de comprimes de bisulfate de clopidogrel |
US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
WO2006138214A1 (fr) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Preparations combinant de l'aspirine et des nanoparticules de clopidogrel |
WO2007035028A1 (fr) * | 2005-09-21 | 2007-03-29 | Chong Kun Dang Pharmaceutical Corp. | Nouveau complexe de resinate de s-clopidogrel et procede pour le produire |
WO2007113857A2 (fr) * | 2006-04-05 | 2007-10-11 | Cadila Healthcare Limited | Formulation de clopidogrel à libération modifiée |
CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
US8404703B2 (en) | 2000-12-25 | 2013-03-26 | Daiichi Sankyo Company, Limited | Medicinal compositions containing aspirin |
KR20130048335A (ko) | 2011-11-02 | 2013-05-10 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
RU2484820C2 (ru) * | 2011-02-24 | 2013-06-20 | Общество с ограниченной ответственностью "Озон" | Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов |
WO2015015062A1 (fr) | 2013-08-02 | 2015-02-05 | Sanofi | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4917255B2 (ja) * | 2003-10-16 | 2012-04-18 | 第一三共ヘルスケア株式会社 | サリチル酸類含有経口組成物 |
KR20070009851A (ko) * | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
KR20070044323A (ko) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 |
EP1900358A1 (fr) * | 2006-09-16 | 2008-03-19 | Cimex Pharma AG | Formulations pharmaceutiques contenant du clopidogrel |
HUP0600839A3 (en) * | 2006-11-14 | 2008-09-29 | Egis Gyogyszergyar Nyrt | Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof |
KR100949273B1 (ko) * | 2008-02-22 | 2010-03-25 | 한올제약주식회사 | 복합제제 |
CN101695496A (zh) * | 2009-10-15 | 2010-04-21 | 苏春华 | 一种含有三氟柳和氯吡格雷的药物组合物 |
JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
JP6004524B2 (ja) * | 2012-07-11 | 2016-10-12 | 大原薬品工業株式会社 | クロピドグレル硫酸塩含有錠剤の製造方法 |
CN104434932B (zh) * | 2014-12-18 | 2017-05-24 | 成都苑东生物制药股份有限公司 | 一种硫酸氢氯吡格雷阿司匹林片药物组合物及其制备方法 |
WO2017037741A1 (fr) * | 2015-09-02 | 2017-03-09 | Sun Pharmaceutical Industries Ltd | Forme posologique solide et compacte à base d'aspirine et de clopidogrel |
CN115737578A (zh) * | 2022-11-23 | 2023-03-07 | 石家庄四药有限公司 | 一种硫酸氢氯吡格雷阿司匹林复方片及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281459A1 (fr) | 1987-02-17 | 1988-09-07 | Sanofi | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant |
US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
WO1997029753A1 (fr) | 1996-02-19 | 1997-08-21 | Sanofi | Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique |
FR2779726A1 (fr) | 1998-06-15 | 1999-12-17 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
-
1999
- 1999-04-30 FR FR9905497A patent/FR2792836B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-25 CA CA002371231A patent/CA2371231A1/fr not_active Abandoned
- 2000-04-25 MX MXPA01011071A patent/MXPA01011071A/es unknown
- 2000-04-25 PL PL00351923A patent/PL351923A1/xx not_active Application Discontinuation
- 2000-04-25 JP JP2000615014A patent/JP2002543137A/ja not_active Withdrawn
- 2000-04-25 IL IL14564800A patent/IL145648A0/xx unknown
- 2000-04-25 BR BR0010194-0A patent/BR0010194A/pt not_active Application Discontinuation
- 2000-04-25 EE EEP200100559A patent/EE200100559A/xx unknown
- 2000-04-25 KR KR1020017013830A patent/KR20020005735A/ko not_active Application Discontinuation
- 2000-04-25 EP EP00922737A patent/EP1178809A1/fr not_active Withdrawn
- 2000-04-25 WO PCT/FR2000/001086 patent/WO2000066130A1/fr not_active Application Discontinuation
- 2000-04-25 TR TR2001/03039T patent/TR200103039T2/xx unknown
- 2000-04-25 EA EA200100959A patent/EA200100959A1/ru unknown
- 2000-04-25 CZ CZ20013887A patent/CZ20013887A3/cs unknown
- 2000-04-25 HU HU0202329A patent/HUP0202329A2/hu unknown
- 2000-04-25 AU AU43036/00A patent/AU4303600A/en not_active Abandoned
- 2000-04-25 SK SK1554-2001A patent/SK15542001A3/sk unknown
- 2000-04-25 NZ NZ514248A patent/NZ514248A/xx unknown
- 2000-04-25 CN CN00807001A patent/CN1359294A/zh active Pending
- 2000-04-28 AR ARP000102020A patent/AR023789A1/es unknown
- 2000-04-28 UY UY26131A patent/UY26131A1/es not_active Application Discontinuation
-
2001
- 2001-09-25 IS IS6084A patent/IS6084A/is unknown
- 2001-10-29 NO NO20015295A patent/NO20015295L/no not_active Application Discontinuation
-
2002
- 2002-05-14 HK HK02103639.9A patent/HK1041823A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281459A1 (fr) | 1987-02-17 | 1988-09-07 | Sanofi | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant |
US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
WO1997029753A1 (fr) | 1996-02-19 | 1997-08-21 | Sanofi | Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique |
FR2779726A1 (fr) | 1998-06-15 | 1999-12-17 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
Non-Patent Citations (3)
Title |
---|
HERBERT J M ET AL: "Clopidogrel hydrogensulfate, SR-25990C: Platelet antiaggregatory.", DRUGS OF THE FUTURE, vol. 18, no. 2, 1993, pages 107 - 112, XP000933409, ISSN: 0377-8282 * |
JAHUAR: "effectiveness...", AM. J. OF CARDIOLOGY, vol. 84, no. 6, September 1999 (1999-09-01), pages 726 - 728, XP000933484 * |
WANG XIANGDONG ET AL: "The effectiveness of the combination of Plavix and aspirin versus Ticlid and aspirin after coronary stent implantation.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no. 2 SUPPL. A, February 1999 (1999-02-01), 48th Annual Scientific Session of the American College of Cardiology;New Orleans, Louisiana, USA; March 7-10, 1999, pages 13A - 14A, XP000933424, ISSN: 0735-1097 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8404703B2 (en) | 2000-12-25 | 2013-03-26 | Daiichi Sankyo Company, Limited | Medicinal compositions containing aspirin |
US8569325B2 (en) | 2000-12-25 | 2013-10-29 | Daiichi Sankyo Company, Limited | Method of treatment with coadministration of aspirin and prasugrel |
US6767913B2 (en) | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
US6737411B2 (en) | 2002-08-02 | 2004-05-18 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
US7259261B2 (en) | 2002-08-02 | 2007-08-21 | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság | Racemization and enantiomer separation of clopidogrel |
WO2005070464A2 (fr) * | 2004-01-21 | 2005-08-04 | Biofarma Ilac Sanayi Ve Ticaret A.S. | Formulation de comprimes de bisulfate de clopidogrel |
WO2005070464A3 (fr) * | 2004-01-21 | 2005-11-03 | Biofarma Ilac Sanayi Ve Ticare | Formulation de comprimes de bisulfate de clopidogrel |
WO2006138214A1 (fr) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Preparations combinant de l'aspirine et des nanoparticules de clopidogrel |
KR100736024B1 (ko) * | 2005-09-21 | 2007-07-06 | 주식회사종근당 | 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 |
WO2007035028A1 (fr) * | 2005-09-21 | 2007-03-29 | Chong Kun Dang Pharmaceutical Corp. | Nouveau complexe de resinate de s-clopidogrel et procede pour le produire |
WO2007113857A3 (fr) * | 2006-04-05 | 2008-02-28 | Cadila Healthcare Ltd | Formulation de clopidogrel à libération modifiée |
WO2007113857A2 (fr) * | 2006-04-05 | 2007-10-11 | Cadila Healthcare Limited | Formulation de clopidogrel à libération modifiée |
RU2484820C2 (ru) * | 2011-02-24 | 2013-06-20 | Общество с ограниченной ответственностью "Озон" | Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов |
KR20130048335A (ko) | 2011-11-02 | 2013-05-10 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
WO2013065936A1 (fr) * | 2011-11-02 | 2013-05-10 | 한국유나이티드제약 주식회사 | Agent complexe contenant du clopidogrel et de l'aspirine |
CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
WO2015015062A1 (fr) | 2013-08-02 | 2015-02-05 | Sanofi | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
Also Published As
Publication number | Publication date |
---|---|
FR2792836A1 (fr) | 2000-11-03 |
AR023789A1 (es) | 2002-09-04 |
SK15542001A3 (sk) | 2002-02-05 |
NO20015295L (no) | 2001-12-21 |
PL351923A1 (en) | 2003-06-30 |
UY26131A1 (es) | 2000-12-29 |
HK1041823A1 (zh) | 2002-07-26 |
EP1178809A1 (fr) | 2002-02-13 |
CZ20013887A3 (cs) | 2002-02-13 |
CN1359294A (zh) | 2002-07-17 |
KR20020005735A (ko) | 2002-01-17 |
AU4303600A (en) | 2000-11-17 |
CA2371231A1 (fr) | 2000-11-09 |
JP2002543137A (ja) | 2002-12-17 |
HUP0202329A2 (en) | 2002-10-28 |
IS6084A (is) | 2001-09-25 |
EE200100559A (et) | 2003-02-17 |
BR0010194A (pt) | 2002-02-13 |
MXPA01011071A (es) | 2002-07-22 |
NO20015295D0 (no) | 2001-10-29 |
IL145648A0 (en) | 2002-06-30 |
EA200100959A1 (ru) | 2002-06-27 |
FR2792836B3 (fr) | 2001-07-27 |
NZ514248A (en) | 2003-06-30 |
TR200103039T2 (tr) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1178809A1 (fr) | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel | |
US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
RU2240795C2 (ru) | Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления | |
EP0330532B1 (fr) | Nouvelle forme galénique du fénofibrate | |
JP2720932B2 (ja) | 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤 | |
US6180138B1 (en) | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption | |
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
FR2460667A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
RU2238087C2 (ru) | Композиции контролируемого высвобождения, содержащие нимесулид | |
FR2585570A1 (fr) | Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue | |
FR2561524A1 (fr) | Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage | |
HU186078B (en) | Process for producing pharmaceutical compositions for peroral application containing dipyridamol | |
EP1108424B2 (fr) | Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale | |
JPH02164824A (ja) | 分散性製剤 | |
JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
EP1353663B1 (fr) | Comprimes de fenofibrate | |
PL194847B1 (pl) | Sposób wytwarzania nowych fenofibratowych preparatów galenowych, otrzymane preparaty galenowe i zastosowanie ciekłego medium | |
EP2814465B1 (fr) | Formule pharmaceutique à stabilité améliorée | |
US5290569A (en) | Coated composition and its preparation process | |
CN114146089B (zh) | 含依非韦伦、替诺福韦和恩曲他滨的药物组合物 | |
FR2489146A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
KR20100041780A (ko) | 옥스카르바제핀을 포함하는 방출 제어형 고체 제제의 제조 방법 및 그에 의해 얻어질 수 있는 제제 | |
EP2946771B1 (fr) | Formulation de comprimé dispersible dans l'eau comprenant du déférasirox | |
JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 | |
SK15552000A3 (sk) | Stabilné prostriedky obsahujúce levosimendan a kyselinu algínovú |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807001.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 514248 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2000 615014 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100959 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/03039 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2371231 Country of ref document: CA Ref document number: 2371231 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15542001 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017013830 Country of ref document: KR Ref document number: PV2001-3887 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018550 Country of ref document: US Ref document number: PA/a/2001/011071 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000922737 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013830 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000922737 Country of ref document: EP Ref document number: PV2001-3887 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000922737 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-3887 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017013830 Country of ref document: KR |